CGTX:NASDAQ, Cognition Therapeutics, Inc.
CGTX stock overview
Cognition Therapeutics, Inc. (CGTX:NASDAQ) closed at $0.582 on November 20, 2026,
down 3.06% on the day.
The stock trades 67.8% below its 52-week high of $1.81
and 5.9% above its 52-week low of $0.550.
Over the past year, it lost 61.9%.
Cognition Therapeutics, Inc. is part of the Health Care sector.
Key figures
- Price
- $0.582
- Day change
- -3.06%
- Volume
- 665,092
- Average volume
- 459,367
- Market cap
- 55M+
- 52-week range
- $0.550 – $1.81
- 50-day average
- $0.813
- 200-day average
- $1.02
Price action over the past year
In 252 trading sessions since November 20, 2025, CGTX closed higher on 105 days (42%).
Its best day was March 31, 2026 (+27.73%) and its worst was June 24, 2026 (-38.18%).
The stock moved 10% or more in a single session 17 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
CGTX news
-
Nov 17, 2026:
Cognition Therapeutics Announces CTAD Poster Highlighting Screening Efficiencies with p-Tau217 in the Ongoing Phase 2 START Study
-
Nov 10, 2026:
What Makes Cognition Therapeutics (CGTX) a New Buy Stock
-
Nov 9, 2026:
Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
-
Nov 5, 2026:
Cognition Therapeutics, Inc. Q3 2026 Earnings Call Summary
-
Nov 5, 2026:
Cognition Tx (CGTX) Q3 2026 Earnings Call Transcript
-
Nov 5, 2026:
Cognition Therapeutics Q3 Earnings Call Highlights
-
Nov 5, 2026:
Cognition Therapeutics Narrows Loss And Lands FDA Alignment On A Leaner DLB Phase 3, But The Pivotal Trial Is Still Unfunded
-
Nov 5, 2026:
Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
About Cognition Therapeutics, Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
Similar stocks
Find more stocks like CGTX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.